Atf4 Antibody

What is ATF4 and what are its key functions in cellular physiology?

ATF4 is a basic leucine-zipper (bZip) transcription factor that plays central roles in various cellular stress responses. It accumulates predominantly in osteoblasts, where it regulates terminal osteoblast differentiation and bone formation . As a key component of the integrated stress response (ISR), ATF4 is activated during various cellular stresses, including endoplasmic reticulum (ER) stress, amino acid deprivation, and oxidative stress. ATF4 regulates amino acid metabolism, cellular redox state, and coordinates anti-stress responses to maintain cellular homeostasis . It also participates in regulating age-related and diet-induced obesity and glucose homeostasis in mammals, indicating its diverse physiological functions beyond stress response.

What are the common alternative names for ATF4 that researchers should recognize?

When searching literature or antibody products related to ATF4, researchers should be aware of several alternative nomenclature:

• CREB-2 or CREB2 (cAMP-responsive element-binding protein 2)

• TAXREB67 or TXREB (Tax-responsive element binding protein 67)

• Cyclic AMP-dependent transcription factor ATF-4

• DNA-binding protein TAXREB67

Recognizing these alternative names is essential for comprehensive literature searches and when evaluating antibody specificity information.

How should I select the most appropriate ATF4 antibody for my specific research application?

Selecting an optimal ATF4 antibody requires careful consideration of several factors:

• Application compatibility: Verify the antibody has been validated for your specific application (WB, IF/ICC, IHC, FC, etc.). The search results indicate that different ATF4 antibodies may be optimized for different applications, with many showing validation for Western blot, while others are specifically validated for immunofluorescence or flow cytometry .

• Species reactivity: Confirm the antibody recognizes ATF4 in your species of interest. Many antibodies show reactivity to human, mouse, and rat ATF4, but cross-reactivity varies between products .

• Clonality: Consider whether a monoclonal or polyclonal antibody is more appropriate for your application. Monoclonal antibodies offer higher specificity for a single epitope, while polyclonal antibodies may provide stronger signals by recognizing multiple epitopes.

• Epitope region: Understanding which region of ATF4 the antibody targets can be important for specific applications, particularly if studying specific domains or post-translational modifications.

• Validation data: Review images and data for your specific application, looking for clean bands at the expected molecular weight (45-50 kDa) or appropriate cellular localization (primarily nuclear).

What validation experiments should I perform to confirm ATF4 antibody specificity?

Rigorous validation is essential for reliable results with ATF4 antibodies:

• Positive and negative controls: Use samples with known ATF4 expression levels. Tunicamycin-treated HeLa cells serve as an excellent positive control as they show increased ATF4 expression due to ER stress induction . HepG2 cells also express detectable levels of basal ATF4 .

• Knockout/knockdown validation: Compare antibody reactivity in wildtype versus ATF4 knockout or siRNA-treated samples. This is the gold standard for antibody validation.

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide before application to samples. Specific signals should be eliminated or significantly reduced.

• Multiple antibody verification: Use several antibodies targeting different epitopes of ATF4 and compare the staining patterns.

• Stress induction: Compare ATF4 detection in basal versus stressed conditions (e.g., tunicamycin treatment). A specific antibody should show increased signal intensity following stress induction.

What are the optimal sample preparation methods for detecting ATF4 using different techniques?

Sample preparation is critical for successful ATF4 detection and varies by application:

For Western Blot:

• Use fresh samples whenever possible to minimize protein degradation.

• Include protease and phosphatase inhibitors in lysis buffers, as ATF4 undergoes post-translational modifications.

• For cell lysis, RIPA buffer or similar detergent-based buffers are suitable.

• Heat samples at 95°C for 5 minutes in reducing sample buffer before loading.

• Load adequate protein (30-50 μg of total protein per lane) to ensure detection of ATF4, which may be expressed at low levels under basal conditions.

For Immunofluorescence/ICC:

• Fix cells with 4% paraformaldehyde for 15 minutes at room temperature.

• Permeabilize thoroughly with 0.1-0.5% Triton X-100, as ATF4 is primarily nuclear.

• Block with 5% normal serum or BSA for at least 1 hour.

• For stress-induced ATF4, treat cells with appropriate stressors (e.g., tunicamycin) 6-12 hours before fixation .

For Flow Cytometry:

• Ensure thorough fixation and permeabilization for intracellular/nuclear staining.

• Use commercially available permeabilization buffers specifically designed for nuclear antigens.

• For intracellular flow cytometry, the recommended amount is approximately 0.60 μg of antibody per 10^6 cells .

What are the recommended protocols for inducing ATF4 expression in experimental models?

Researchers can induce ATF4 expression through various stress conditions:

• ER stress induction:

  • Tunicamycin (1-5 μg/mL, 6-24 hours): Inhibits N-linked glycosylation and induces robust ATF4 expression in most cell types .

  • Thapsigargin (0.1-1 μM, 6-24 hours): Depletes ER calcium stores, triggering the unfolded protein response.

• Amino acid deprivation:

  • Culture cells in amino acid-deficient media for 2-24 hours to activate the GCN2-ATF4 pathway.

• Oxidative stress:

  • Arsenite (10-50 μM, 1-6 hours): Induces oxidative stress and activates the integrated stress response.

• Hypoxia:

  • Culture cells under low oxygen conditions (1% O₂) for 6-24 hours.

When inducing ATF4 expression, researchers should consider performing a time course to determine optimal treatment duration, as expression may peak at specific timepoints. Additionally, monitoring cell viability is important, as prolonged stress can induce apoptosis.

What dilutions and protocols are recommended for using ATF4 antibodies in different applications?

The optimal dilutions and protocols for ATF4 antibodies vary by application:

For Western Blot:

• Typical dilution range: 1:500-1:1000

• Protocol: Standard Western blotting procedure with overnight incubation at 4°C for primary antibody

• Expected result: A band at 45-50 kDa representing ATF4

For Immunofluorescence/ICC:

• Recommended dilution: 1:50-1:500

• Protocol: Standard IF protocol with adequate permeabilization for nuclear antigen detection

• Incubate with primary antibody overnight at 4°C for optimal results

For Flow Cytometry (Intracellular):

• Recommended amount: 0.60 μg per 10^6 cells in a 100 μl suspension

• Protocol: Follow standard intracellular staining protocols with appropriate fixation and permeabilization

Researchers should always titrate antibodies in their specific experimental system to determine optimal conditions, as the required dilution may vary depending on cell type, fixation method, and detection system.

How should I interpret multiple bands or unexpected molecular weights when using ATF4 antibodies in Western blot?

When performing Western blot with ATF4 antibodies, researchers may encounter multiple bands or unexpected molecular weights, requiring careful interpretation:

• Expected primary band: ATF4 should appear at approximately 45-50 kDa, despite its calculated molecular weight of 38.6 kDa . This discrepancy is due to post-translational modifications and is normal.

• Lower molecular weight bands may represent:

  • Degradation products due to sample processing or storage

  • Alternative splice variants of ATF4

  • Proteolytic processing products with potential biological significance

• Higher molecular weight bands may indicate:

  • Post-translational modifications such as phosphorylation (ATF4 is known to be phosphorylated at sites including Ser245)

  • Protein complexes not fully dissociated during sample preparation

  • Non-specific binding of the antibody

Validation approaches for confirming band identity include:

• Stress induction: Specific ATF4 bands should increase in intensity after treatment with ER stressors like tunicamycin

• Comparison with positive control samples (e.g., HepG2 or tunicamycin-treated HeLa cells)

• Peptide competition assays to confirm specificity

What are common experimental challenges when working with ATF4 antibodies and how can they be addressed?

Researchers commonly encounter several challenges when working with ATF4 antibodies:

• Weak or no signal:

  • Solution: Induce ATF4 expression with stressors like tunicamycin prior to analysis

  • Increase protein loading amount (50-80 μg)

  • Optimize antibody concentration through titration experiments

  • Use more sensitive detection methods (enhanced chemiluminescence for Western blot)

• High background:

  • Solution: Increase blocking time or concentration (5% BSA or milk)

  • Dilute primary antibody further

  • Increase number and duration of washes

  • Test different blocking agents

• Inconsistent results between experiments:

  • Solution: Standardize stress induction protocols (exact timing, concentration)

  • Use consistent sample preparation methods

  • Consider using the same antibody lot for critical experiments

  • Process all experimental conditions in parallel

• Application-specific issues:

  • For IF/ICC: Ensure adequate permeabilization for nuclear antigen detection

  • For flow cytometry: Optimize fixation and permeabilization conditions for intracellular staining

  • For IHC: Perform proper antigen retrieval to expose epitopes

How can I distinguish between specific and non-specific staining when using ATF4 antibodies in imaging applications?

Distinguishing specific from non-specific staining requires systematic evaluation:

• Localization pattern: ATF4 is primarily nuclear, so specific staining should be predominantly localized to nuclei. Cytoplasmic or membranous staining may indicate non-specific binding.

• Stress-dependent expression: ATF4 expression increases dramatically under stress conditions. Compare staining patterns between basal and stressed conditions (e.g., tunicamycin-treated cells show increased nuclear ATF4) .

• Controls for validation:

  • Positive controls: HepG2 cells or tunicamycin-treated HeLa cells, which have confirmed ATF4 expression

  • Negative controls: Secondary antibody-only controls, isotype controls

  • Competitive inhibition: Pre-incubation with immunizing peptide should eliminate specific staining

• Signal characteristics:

  • Specific staining typically has defined boundaries and consistent patterns

  • Non-specific staining often appears diffuse, inconsistent, or with unusual localization

When optimizing immunofluorescence protocols, start with the manufacturer's recommended dilution range (1:50-1:500) and adjust based on signal-to-noise ratio .

How can ATF4 antibodies be used to study the unfolded protein response and integrated stress response?

ATF4 antibodies are valuable tools for investigating stress response pathways:

• Monitoring pathway activation:

  • Western blot analysis of ATF4 provides a direct readout of integrated stress response (ISR) activation

  • Combine with analysis of upstream factors (phospho-eIF2α) and downstream targets (CHOP) for comprehensive pathway assessment

  • Use time-course experiments to track the kinetics of ISR activation

• Subcellular localization studies:

  • Immunofluorescence with ATF4 antibodies reveals nuclear translocation during stress

  • Co-staining with other stress response factors helps map pathway interactions

• Target gene regulation:

  • ChIP assays using ATF4 antibodies can identify direct transcriptional targets

  • Combine with gene expression analysis to correlate ATF4 binding with target regulation

• Compound screening applications:

  • Use ATF4 detection to screen compounds for modulation of stress response pathways

  • Develop high-content imaging assays based on ATF4 nuclear localization

• Disease model applications:

  • Study differential ATF4 activation in cancer, neurodegenerative disease, or metabolic disorder models

  • Correlate ATF4 levels with disease progression or treatment response

What methodologies are available for studying ATF4 post-translational modifications?

Studying ATF4 post-translational modifications requires specialized approaches:

• Phospho-specific antibodies:

  • Some suppliers offer antibodies specific to phosphorylated ATF4 (e.g., phospho-Ser245)

  • Compare phosphorylated vs. total ATF4 to assess activation state

  • Use in parallel with kinase inhibitors to identify regulatory pathways

• Detection methods:

  • Phos-tag SDS-PAGE to separate phosphorylated forms

  • Western blot comparison before and after phosphatase treatment

  • Immunoprecipitation followed by phospho-specific Western blotting

• Functional studies:

  • Site-directed mutagenesis of key phosphorylation sites

  • Correlation of phosphorylation status with transcriptional activity

  • Analysis of kinase-dependent regulation of ATF4 stability and function

The observed molecular weight of ATF4 (45-50 kDa) compared to its calculated weight (38.6 kDa) is partially due to these post-translational modifications .

How can ATF4 antibodies be optimized for chromatin immunoprecipitation (ChIP) studies?

For successful ChIP experiments with ATF4 antibodies:

• Experimental design considerations:

  • Induce ATF4 expression before ChIP (e.g., 6-8 hours of tunicamycin treatment)

  • Include known ATF4 target genes as positive controls

  • Use ATF4-deficient cells as negative controls

• Antibody selection:

  • Choose antibodies validated specifically for ChIP applications

  • Polyclonal antibodies often perform well in ChIP assays

  • Consider epitope accessibility in the chromatin context

• Protocol optimization:

  • Optimize crosslinking conditions (typically 1% formaldehyde for 10 minutes)

  • Ensure chromatin is sheared to appropriate fragment size (200-500 bp)

  • Determine optimal antibody amount through titration (typically 2-5 μg per IP)

  • Include appropriate negative controls (IgG, input)

• Analysis methods:

  • qPCR for targeted analysis of specific binding sites

  • ChIP-seq for genome-wide binding profile

  • Analyze enrichment relative to input and negative controls

ChIP with ATF4 antibodies can reveal direct transcriptional targets and provide insight into the genome-wide impact of stress response pathways.

What are the considerations for studying ATF4 in different tissue and cell types?

ATF4 expression and function varies across tissues, requiring specific experimental approaches:

• Tissue-specific expression patterns:

  • Highly expressed in osteoblasts where it regulates bone formation

  • Expressed at varying levels in liver, kidney, brain, and other tissues

  • May show different basal and stress-induced levels across cell types

• Cell type-specific considerations:

  • Different optimal stress inducers depending on cell type

  • Varying antibody performance across cell types

  • Need for cell type-specific positive controls

• Recommended cell models:

  • HepG2 cells: Show detectable basal ATF4 expression

  • HeLa cells: Respond well to tunicamycin treatment for ATF4 induction

  • Osteoblasts: High physiological expression of ATF4

• Technical adaptations:

  • Adjust fixation protocols for different tissue types

  • Optimize antibody dilutions based on expression levels

  • Consider tissue-specific autofluorescence issues for imaging applications

How are ATF4 antibodies used in studying disease mechanisms and potential therapeutics?

ATF4 antibodies are valuable tools in disease research:

• Cancer research applications:

  • Monitor ATF4 activation in response to tumor microenvironment stresses

  • Study ATF4-dependent survival mechanisms in cancer cells

  • Evaluate ATF4 as a biomarker for therapeutic response

• Neurodegenerative disease studies:

  • Examine ATF4 induction in models of protein misfolding diseases

  • Correlate with markers of neuronal stress and degeneration

  • Evaluate potential neuroprotective interventions

• Metabolic disorder investigations:

  • Study ATF4's role in obesity and glucose homeostasis

  • Examine ATF4 activation in models of diabetes and metabolic syndrome

  • Analyze tissue-specific effects in liver, adipose tissue, and muscle

• Therapeutic development applications:

  • Screen compounds for modulation of ATF4 expression or activity

  • Monitor on-target effects of drugs targeting stress response pathways

  • Develop ATF4-based biomarkers for clinical trials

• Technical considerations:

  • Correlate protein expression with downstream target activation

  • Consider tissue heterogeneity in disease samples

  • Use multiple methodologies for comprehensive pathway analysis